Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05568316
Other study ID # 2020/151-2879
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 1, 2020
Est. completion date February 10, 2022

Study information

Verified date August 2022
Source Saglik Bilimleri Universitesi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Colorectal cancer is among the top three types of cancer that are most common and causes death worldwide.Nutritional support is widely used in elective colorectal surgery patients, as nutritional status is an important factor affecting clinical outcomes. European Society for Clinical Nutrition and Metabolism (ESPEN, 2016) emphasizes that nutritional supplementation with compounds such as amino acids, arginine, glutamine, and fish oil (omega 3) improves postoperative recovery. Glutamine; it becomes an essential amino acid under stress. It is an energy substrate for cells such as intestinal mucosal cells and lymphocytes, a material for glutathione synthesis, and a potent antioxidant, which also increases heat shock protein expression. In stressful conditions, arginine is the primary fuel source for T cells and is required for nitric oxide synthesis; therefore, it helps maintain immune function. Omega 3; It plays a role in the treatment of inflammation and improves wound healing. In addition, EPA and DHA increase the immune response by improving lymphocyte function. RNA; They are essential for maturation, proliferation, and function in nearly all biochemical processes, in rapidly proliferating cells such as T cells. studies have shown that immunonutrition (IMN) formulas enriched with biologically active compounds may be more effective in reducing infection complications and shortening postoperative hospital stays. This study aimed to investigate the additional effects of perioperative compared with preoperative immunonutrition on anthropometric, nutritional, and biochemical parameters, complications, and the length of hospital stay in patients with colorectal cancer.


Description:

Colorectal cancer is one of the five most common cancer types in men and women worldwide. Cancer malnutrition is seen in patients with colorectal cancer, and this adversely affects the prognosis of the disease. Major operations performed may lead to dysfunction in body homeostasis, impaired defense mechanisms and inflammatory response, increasing the risk of postoperative complications and prolonging hospital stay. Nutritional support products enriched with special compounds such as arginine, glutamine, and omega3 may contribute to the daily energy intake of patients, as well as support the immune system, increase wound healing, and reduce the risk of infection. It is well-documented that preoperative and perioperative compared to no immunonutrition effectively reduce the risk of developing infectious complications and the length of hospital stay. Unless, studies on this subject are very few, especially in our country, Turkey, and their results are contradictory. The aim of this study is to investigate the additional effects of perioperative compared with preoperative immunonutrition (IMN) on anthropometric, nutritional, biochemical parameters, hospital stay and postoperative complication in patients with colorectal cancer. The hypotheses of this study are as follows: H0: There is no difference between the consumption of perioperative compared with preoperative immunonutrition (IMN) on anthropometric, nutritional, biochemical parameters, hospital stay and postoperative complication in patients with colorectal cancer. H1: Perioperative immunonutrition compare to preoperative has a positive effect in improving the anthropometric measurements, nutritional and biochemical parameters, hospital stay and postoperative complication in patients with colorectal cancer. Primary purpose: To evaluate the effects of IMN on anthropometric measurements, nutritional and biochemical values of participants in groups. Secondary purpose: To evaluate the effects of IMN on postoperative complications and length of hospital stay in groups. The study was conducted as a single-blind prospective randomized controlled clinical trial at a single institution, Haydarpasa Numune Training and Research Hospital General Surgery Clinic, Istanbul, Turkey, between November 2020 and October 2021. The participants included consecutive patients undergoing colorectal cancer surgery.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date February 10, 2022
Est. primary completion date October 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Diagnosed with colorectal cancer, - from 18 years up to 65 years old, - To be volunteer, - Informed written consent Exclusion Criteria: - Under the age of 18, - Above the age of 65 - To be pregnant, - Acute and chronic renal failure, cirrhosis, advanced COPD, mechanical intestinal obstruction, metastasis, presence of sepsis, - The ejection fraction is below 35%.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Preoperative Immunonutrition
Participants consumed oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before surgery. The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period.
Perioperative Immunonutrition
Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet. The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period.

Locations

Country Name City State
Turkey Saglik Bilimleri University Istanbul Uskudar

Sponsors (2)

Lead Sponsor Collaborator
Saglik Bilimleri Universitesi Haydarpasa Numune Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (5)

Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hutterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Muhlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015. Epub 2016 Aug 6. — View Citation

Bharadwaj S, Trivax B, Tandon P, Alkam B, Hanouneh I, Steiger E. Should perioperative immunonutrition for elective surgery be the current standard of care? Gastroenterol Rep (Oxf). 2016 May;4(2):87-95. doi: 10.1093/gastro/gow008. Epub 2016 Apr 14. — View Citation

Fukatsu K. Role of nutrition in gastroenterological surgery. Ann Gastroenterol Surg. 2019 Feb 25;3(2):160-168. doi: 10.1002/ags3.12237. eCollection 2019 Mar. — View Citation

Karimian J, Hadi A, Salehi-Sahlabadi A, Kafeshani M. The Effect of Arginine Intake on Colorectal Cancer: a Systematic Review of Literatures. Clin Nutr Res. 2019 Jul 25;8(3):209-218. doi: 10.7762/cnr.2019.8.3.209. eCollection 2019 Jul. — View Citation

Moya P, Soriano-Irigaray L, Ramirez JM, Garcea A, Blasco O, Blanco FJ, Brugiotti C, Miranda E, Arroyo A. Perioperative Standard Oral Nutrition Supplements Versus Immunonutrition in Patients Undergoing Colorectal Resection in an Enhanced Recovery (ERAS) Protocol: A Multicenter Randomized Clinical Trial (SONVI Study). Medicine (Baltimore). 2016 May;95(21):e3704. doi: 10.1097/MD.0000000000003704. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Nutritional Status The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Score >3: The patient is at risk for nutrition and a nutrition facility is started Score <3: one should be scanned. If there is a major operation plan, a nutrition plan should also be developed. At the beginning of the study (7 days before the operation)
Primary Anthropometric Measurements Height in meters was measured by researchers at the begining of the study. At the beginning of the study (7 days before the operation)
Primary Anthropometric Measurements Body weight in kilogram was measured by researchers. At the beginning of the study (7 days before the operation)
Primary Anthropometric Measurements Weight and height will be combined to report BMI in kg/m^2 At the beginning of the study (7 days before the operation)
Primary Anthropometric Measurements Middle-upper arm circumference (MUAC) in centimeter was measured by using tape measure. At the beginning of the study (7 days before the operation)
Primary Biochemical Measurements Albumin levels in g/dL of participants was recorded from hospital's patients form. At the beginning of the study (7 days before the operation)
Primary Biochemical Measurements Prealbumin levels in mg/dL of participants was recorded from hospital's patients form. At the beginning of the study (7 days before the operation)
Primary Biochemical Measurements Fasting plasma glucose (FPG) mg/dL in of participants was recorded from hospital's patients form. At the beginning of the study (7 days before the operation)
Primary Biochemical Measurements Alanine aminotransferase (ALT) in IU/L of participants was recorded from hospital's patients form. At the beginning of the study (7 days before the operation)
Primary Biochemical Measurements Aspartate aminotransferase (AST) in IU/L of participants was recorded from hospital's patients form. At the beginning of the study (7 days before the operation)
Primary Biochemical Measurements C-reactive protein (CRP) in mg/L of participants was recorded from hospital's patients form. At the beginning of the study (7 days before the operation)
Primary Anthropometric Measurements Body weight in kilogram was measured by researchers. 7th day after the operation
Primary Anthropometric Measurements Weight and height will be combined to report BMI in kg/m^2 7th day after the operation
Primary Anthropometric Measurements Middle-upper arm circumference (MUAC) in centimeter was measured by using tape measure. 7th day after the operation
Primary Biochemical Measurements Albumin levels in g/dL of participants was recorded from hospital's patients form. On the operation day (Day 0)
Primary Biochemical Measurements Prealbumin levels in mg/dL of participants was recorded from hospital's patients form. On the operation day (Day 0)
Primary Biochemical Measurements Fasting plasma glucose (FPG) mg/dL in of participants was recorded from hospital's patients form. On the operation day (Day 0)
Primary Biochemical Measurements Alanine aminotransferase (ALT) in IU/L of participants was recorded from hospital's patients form. On the operation day (Day 0)
Primary Biochemical Measurements Aspartate aminotransferase (AST) in IU/L of participants was recorded from hospital's On the operation day (Day 0)
Primary Biochemical Measurements C-reactive protein (CRP) in mg/L of participants was recorded from hospital's patients form. On the operation day (Day 0)
Primary Biochemical Measurements Albumin levels in g/dL of participants was recorded from hospital's patients form. 7th day after the operation
Primary Biochemical Measurements Prealbumin levels in mg/dL of participants was recorded from hospital's patients form. 7th day after the operation
Primary Biochemical Measurements Fasting Plasma glucose (FPG) mg/dL in of participants was recorded from hospital's patients form. 7th day after the operation
Primary Biochemical Measurements Alanine aminotransferase (ALT) in IU/L of participants was recorded from hospital's patients form. 7th day after the operation
Primary Biochemical Measurements Aspartate aminotransferase (AST) in IU/L of participants was recorded from hospital's patients form. 7th day after the operation
Primary Biochemical Measurements C-reactive protein (CRP) in mg/L of participants was recorded from hospital's patients form. 7th day after the operation
Secondary Postoperative Complications of Participants Infections (such as urinary tract, wound infections) and complications were recorded during the postoperative period. After the operation, up to 30 days.
Secondary Lenght of Hospital Stay of Participants The length of patients' hospital stay were recorded during the postoperative period. After the operation, up to 30 days.
See also
  Status Clinical Trial Phase
Suspended NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Not yet recruiting NCT05775146 - SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases Phase 2
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1